Inventor · disambiguated record
Laxman Eltepu
Also filed as: ELTEPU LAXMAN
21 granted patents·12 pending applications·309 citations·filing 2000–2024
95Inventor score
Files withARBUTUS BIOPHARMA CORP13ALIGOS THERAPEUTICS INC6SIRIUS THERAPEUTICS INC4BRADSHAW CURT W3MANOHARAN MUTHIAH3
Top patents by PatentIndex Score
33 records- 0199US9682139B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Jun 20, 2017·46 cites·20 claims
- 0298US9186325B2Lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2009·Granted Nov 17, 2015·100 cites·19 claims
- 0398US8999351B2Lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2009·Granted Apr 7, 2015·102 cites·15 claims
- 0497US9764036B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Sep 19, 2017·19 cites·22 claims
- 0596US10117941B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 6, 2018·12 cites·14 claims
- 0695US11549110B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2022·Granted Jan 10, 2023·5 cites·30 claims
- 0795US10821186B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2018·Granted Nov 3, 2020·4 cites·24 claims
- 0893US12453776B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2024·Granted Oct 28, 2025·0 cites·46 claims
- 0993US11077197B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Aug 3, 2021·3 cites·17 claims
- 1092US12129469B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·30 claims
- 1191US9707292B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Jul 18, 2017·5 cites·12 claims
- 1289US12042541B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2023·Granted Jul 23, 2024·0 cites·23 claims
- 1388US2023381319A1Novel lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2023·Application pending·0 cites
- 1484US11203611B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useSOLSTICE BIOLOGICS LTD·Filed 2018·Granted Dec 21, 2021·5 cites·35 claims
- 1581US11981703B2Polynucleotide constructsSIRIUS THERAPEUTICS INC·Filed 2017·Granted May 14, 2024·2 cites·13 claims
- 1681US11597744B2Chiral phosphoramidite auxiliaries and methods of their useSIRIUS THERAPEUTICS INC·Filed 2018·Granted Mar 7, 2023·2 cites·20 claims
- 1778US11712476B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2021·Granted Aug 1, 2023·0 cites·16 claims
- 1878US2023332153A1Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofALIGOS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1978US2021162053A1Novel lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2020·Application pending·0 cites
- 2076US12454691B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2022·Granted Oct 28, 2025·0 cites·29 claims
- 2174US10835612B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 17, 2020·0 cites·17 claims
- 2274US2024247025A1Polynucleotide constructsSIRIUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2373US12269839B2Chiral phosphoramidite auxiliaries and methods of their useSIRIUS THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·13 claims
- 2470US2022364096A1Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofALIGOS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2568US2018064807A1Novel lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Application pending·0 cites
- 2666US12351598B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useTALLAC THERAPEUTICS INC·Filed 2021·Granted Jul 8, 2025·0 cites·44 claims
- 2766US2023383296A1Modified gapmer oligomers and methods of use thereofALIGOS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2863US2012095075A1Novel lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2011·Application pending·0 cites
- 2961US6441198B1Podophyllotoxin dimer as DNA topoisomerase II inhibitors, and a process for the preparation thereforeCOUNCIL SCIENT IND RES·Filed 2000·Granted Aug 27, 2002·3 cites·9 claims
- 3053US2020392498A1Polynucleotide constructs having bioreversible and non-bioreversible groupsSOLSTICE BIOLOGICS LTD·Filed 2020·Application pending·0 cites
- 3143US2016257961A1Polynucleotide constructs having disulfide groupsBRADSHAW CURT W·Filed 2014·Application pending·0 cites
- 3243US2017114341A1Polynucleotide constructs having bioreversible and non-bioreversible groupsBRADSHAW CURT W·Filed 2015·Application pending·0 cites
- 3339US2019194655A1Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioateBRADSHAW CURT W·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laxman Eltepu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →